Navigation Links
What would happen without PSA testing?
Date:7/29/2012

A new analysis has found that doing away with PSA (prostate specific antigen) testing for prostate cancer would likely cause three times as many men to develop advanced disease that has spread to other parts of the body before being diagnosed. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study suggests that PSA testing and early detection may prevent approximately 17,000 men each year from having such advanced prostate cancer at diagnosis.

PSA testing has come under fire recently as a potentially ineffective screen for prostate cancer. Last year a government panel reviewed the available evidence and concluded that PSA testing has little or no benefit and that doctors are finding and treating non-aggressive cancers that are not likely to cause symptoms or be lethal. Therefore, many men may be experiencing serious treatment side effects such as incontinence and erectile dysfunction for no reason.

To see what might happen if PSA testing were abandoned, Edward Messing, MD, of the University of Rochester Medical Center, and his team looked at information from the years immediately before routine PSA testing was done (1983-1985) and compared it to the current era of widespread PSA testing (2006 to 2008). The information for the analysis came from the nation's largest cancer registry, the Surveillance, Epidemiology, and End Results (SEER) database. The researchers were particularly interested in the records of patients who had advanced prostate cancer that had already spread to other parts of the body at the time of diagnosis. These cases are generally incurable and always cause significant symptoms very quickly if left untreated.

The investigators found that approximately 8,000 cases of prostate cancer had already spread to distant sites (i.e. metastases) at the time of diagnosis in the United States in 2008 (the most recent SEER year). Next, they designed a mathematical model that used pre-PSA incidence rates of metastatic disease from the mid-1980s to estimate the number of such advanced cases that would be expected to occur in 2008 if PSA screening had not been done. They predicted the number would be approximately 25,000, which is about three times greater than the number actually observed.

"Our findings are very important in light of the recent controversy over PSA testing," said Dr. Messing. "Although there are trade-offs associated with the PSA test and many factors influence the disease outcome, our data clearly indicate that not doing the PSA test will result in many more men presenting with far advanced prostate cancer. Almost all men with clinically apparent metastases at initial diagnosis will die from prostate cancer," he added.

Prostate cancer is the second leading cause of cancer death in the male population. In 2012 an estimated 241,740 new cases will be diagnosed and 28,000 deaths will occur. Prognosis depends on whether the cancer has spread, and the degree to which the cancer cells are abnormal.


'/>"/>
Contact: Amy Molnar
sciencenewsroom@wiley.com
Wiley
Source:Eurekalert

Related medicine news :

1. Would sliding back to pre-PSA era cancel progress in prostate cancer?
2. Expanding Access to Medicaid Would Save Lives: Study
3. NYC Ban on Super-Sized Sodas Would Cut Consumers Calories: Study
4. Reducing Ozone Limits Would Save Lives, Report States
5. Lowering the national ozone standard would significantly reduce mortality and morbidity
6. How much would our health benefit from leaving the car at home?
7. New process would make anti-malarial drug less costly
8. MSU plan would control deadly tsetse fly
9. What happens when we sunburn
10. Predicting post-traumatic stress disorder before it happens
11. Bloodstream scavenger inhibits clotting without increased bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand marijuana ... the Icahn School of Medicine at Mount Sinai has found. The study was ... children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite of ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, ... Device Remote Control through a new partnership with Splashtop Inc. This remote control ... mobile solutions to help businesses maximize their uptime and productivity. , Wavelink offers ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
(Date:12/7/2016)... Yorba Linda, Ca (PRWEB) , ... December 07, 2016 , ... ... to attain that funding is with useful, properly analyzed data. The team at Beckman ... generation to address the 'need for speed' and the need to operate in a ...
(Date:12/7/2016)... ... 2016 , ... A quote from Dr. Edward Hallowell, host of CRN International’s ... offer a rare glimpse into the mind of those people with ADHD. , Dr. ... author, has described people with ADHD as having “Ferrari engines for a brain, with ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) ... of reducing expression of Ki67, a biomarker of cell ... the Phase 2 trial presented during the official press ... (SABCS) evaluated abemaciclib, both alone or in combination with ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... REPORT OBJECTIVES The report ... intelligence on a market segment, based on geography. ... in the report. The primary objectives of this ... intelligence through detailed segmentation, 2) market size and ... developments, market situation, trends, 3) detailed analysis of ...
Breaking Medicine Technology: